Nodular Regenerative Hyperplasia of the Liver Associated With Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor in a Patient With Metastatic Renal Cell Carcinoma.
作者信息
Rudolph Shannon, Li Mingjia, Gheeya Jinesh, Zimmerman Danielle, Yin Ming, Clinton Steven K, Parwani Anil V, Yang Yuanquan
机构信息
The College of Medicine, The Ohio State University, Columbus, OH.
Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
出版信息
JCO Precis Oncol. 2023 Apr;7:e2200625. doi: 10.1200/PO.22.00625.
Abstract
摘要
相似文献
1
Nodular Regenerative Hyperplasia of the Liver Associated With Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor in a Patient With Metastatic Renal Cell Carcinoma.
JCO Precis Oncol. 2023 Apr;7:e2200625. doi: 10.1200/PO.22.00625.
2
Efficacy of everolimus in patients with advanced renal cell carcinoma refractory or intolerant to VEGFR-TKIs and safety compared with prior VEGFR-TKI treatment.
Jpn J Clin Oncol. 2014 May;44(5):479-85. doi: 10.1093/jjco/hyu018. Epub 2014 Mar 30.
3
New Insights into Adjuvant Renal Cell Carcinoma Treatment with Vascular Endothelial Growth Factor Inhibitors: What Have We Learned So Far?
Eur Urol. 2018 Jan;73(1):1-3. doi: 10.1016/j.eururo.2017.08.020. Epub 2017 Sep 8.
4
Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far.
Hematol Oncol Clin North Am. 2011 Aug;25(4):871-91. doi: 10.1016/j.hoc.2011.04.003.
5
Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys".
Int J Mol Sci. 2019 Apr 17;20(8):1901. doi: 10.3390/ijms20081901.
6
VEGFR-TKI treatment for radiation-induced brain injury after gamma knife radiosurgery for brain metastases from renal cell carcinomas.
Jpn J Clin Oncol. 2023 Mar 30;53(4):355-364. doi: 10.1093/jjco/hyac197.
7
Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience.
BJU Int. 2016 Aug;118(2):264-71. doi: 10.1111/bju.13374. Epub 2015 Dec 13.
8
Optimizing recent advances in metastatic renal cell carcinoma.
Curr Oncol Rep. 2009 May;11(3):218-26. doi: 10.1007/s11912-009-0031-5.
9
Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.
Hematol Oncol Clin North Am. 2011 Aug;25(4):813-33. doi: 10.1016/j.hoc.2011.04.006.
10
Vascular endothelial growth factor-targeted therapy in patients with renal cell carcinoma pretreated with immune checkpoint inhibitors: A systematic literature review.
Cancer Treat Rev. 2024 Jan;122:102652. doi: 10.1016/j.ctrv.2023.102652. Epub 2023 Nov 4.
本文引用的文献
1
Severe tyrosine-kinase inhibitor induced liver injury in metastatic renal cell carcinoma patients: two case reports assessed for causality using the updated RUCAM and review of the literature.
BMC Gastroenterol. 2022 Feb 5;22(1):49. doi: 10.1186/s12876-022-02121-3.
2
Pathologic Manifestations of Gastrointestinal and Hepatobiliary Injury in Immune Checkpoint Inhibitor Therapy.
Arch Pathol Lab Med. 2021 May 1;145(5):571-582. doi: 10.5858/arpa.2020-0070-RA.
3
VEGF in Signaling and Disease: Beyond Discovery and Development.
Cell. 2019 Mar 7;176(6):1248-1264. doi: 10.1016/j.cell.2019.01.021.
4
Nodular Regenerative Hyperplasia Associated With Immune Checkpoint Blockade.
Hepatology. 2018 Dec;68(6):2431-2433. doi: 10.1002/hep.30157. Epub 2018 Nov 5.
5
Reversibility of chemotherapy-related liver injury.
J Hepatol. 2017 Jul;67(1):84-91. doi: 10.1016/j.jhep.2017.02.031. Epub 2017 Mar 9.
6
Occurrence of hepatotoxicity with pazopanib and other anti-VEGF treatments for renal cell carcinoma: an observational study utilizing a distributed database network.
Cancer Chemother Pharmacol. 2016 Sep;78(3):559-66. doi: 10.1007/s00280-016-3112-9. Epub 2016 Jul 20.
7
RUCAM in Drug and Herb Induced Liver Injury: The Update.
Int J Mol Sci. 2015 Dec 24;17(1):14. doi: 10.3390/ijms17010014.
8
Hepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis of randomized clinical trials.
Crit Rev Oncol Hematol. 2015 Mar;93(3):257-76. doi: 10.1016/j.critrevonc.2014.11.006. Epub 2014 Nov 27.
9
Drug-induced nodular regenerative hyperplasia.
Semin Liver Dis. 2014 May;34(2):240-5. doi: 10.1055/s-0034-1375963. Epub 2014 May 31.
10
Nodular regenerative hyperplasia: evolving concepts on underdiagnosed cause of portal hypertension.
World J Gastroenterol. 2011 Mar 21;17(11):1400-9. doi: 10.3748/wjg.v17.i11.1400.
Zotero 插件